B-DOC Regimen Plus Maintenance Feasible for Advanced Gastric Cancer

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine (B-DOC) plus maintenance therapy was feasible and active as first-line therapy in patients with advanced gastric or gastroesophageal adenocarcinoma, a study published in the journal Cancer has shown.1

Researchers found that the median overall survival was 12.0 months (95% CI: 10.2-16.1).

In terms of safety, the most common treatment-emergent grade 3 or worse adverse events were neutropenia (20%), leukopenia (18%), diarrhea (15%), and nausea/vomiting (15%).

The study also demonstrated that the presence of circulating tumor cells at baseline and methylenetetrahydrofolate reductase (MTHFR) 677C>T genotype were strongly associated with progression-free and overall survival.

“Docetaxel-based triplet chemotherapy as a backbone for targeted therapies is feasible and deserves further study,” the authors conclude.